Table 5.
Mean and magnitude of change (effect size) of the different dimensions of sleep measured by the MOS-sleep, according to treatment group
| Dimension of the MOS-sleep | Non-PGB (N = 155)a | PGB monotherapy (N = 473)a | PGB add-on (N = 676)a | P |
|---|---|---|---|---|
| Summary index (0–100) | −9.3 (16.0) [0.55] | −17.3 (18.1) [1.01] | −17.3 (18.1) [1.01] | <0.001 |
| Sleep disturbance (0–100) | −11.2 (18.5) [0.56] | −19.3 (20.1) [0.99] | −20.0 (19.8) [1.02] | <0.001 |
| Snoring (0–100) | 0.9 (23.2) [0.03] | −5.5 (23.6) [0.19] | −5.1 (20.8) [0.18] | 0.001 |
| Shortness of breath (0–100) | −2.1 (27.0) [0.08] | −10.7 (23.8) [0.40] | −12.3 (24.7) [0.47] | <0.001 |
| Sleep quantity, hours | +0.4 (1.2) [0.27] | +0.9 (1.3) [0.64] | +1.0 (1.2) [0.77] | <0.001 |
| Adequacy of sleep (100–0) | +11.3 (21.5) [0.48] | +21.2 (25.3) [0.92] | +20.7 (24.3) [0.89] | <0.001 |
| Daytime somnolence (0–100) | −5.6 (18.9) [0.29] | −10.9 (19.6) [0.57] | −9.5 (19.6) [0.50] | <0.001 |
Values given as mean (standard deviation) [effect size]
MOS Medical Outcomes Study, PGB pregabalin
aTotal number of patients analyzed; some subjects failed to report the data relating to certain variables